ArticlePakistan journal of medical sciences2025
Retrospective analysis of the efficacy of total glycosides of paeony capsules combined with hydroxychloroquine in patients with primary Sjogren's syndrome.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioengineered anti-EpCAM-guided exosome nanocarriers delivering Foxp3 agonist butyrate achieve tissue-specific immunomodulation in autoimmune Sjögren's syndrome.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this retrospective analysis, total glucosides of paeony (TGP) were compared with hydroxychloroquine (HCQ) in the treatment of patients with primary Sjogren's syndrome (pSS). Methods: In this retrospectively analysis, 157 patients with SS treated at the First Affiliated Hospital of Zhejiang University School of Medicine hospital between January 2020 and December 2023 were included. The analysis included the flow rates of saliva and tears before and after treatment in the control group and observation group, as well as levels of white blood cells (WB), hemoglobin (Hb), platelets (PLT), and immunoinflammatory indicators including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum immunoglobulin G (IgG) levels, disease evaluation scores and occurrence of adverse reactions. Results: Clinical baseline data were not statistically significant after six months of treatment between the two groups ( Conclusions: In the treatment of pSS, TGP capsules and HCQ are combined to improve salivary and lacrimal gland function, suppress the release of inflammatory factors, repair damage to the blood system, control disease activity, show significant clinical efficacy, and have few adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.